Neurodegenerative Pathways in Parkinson's Disease: Therapeutic Strategies

被引：44
作者：
Cardoso, S. M. [1 ,2 ]
Moreira, P., I
Agostinho, P.
Pereira, C.
Oliveira, C. R.
机构：
[1] Univ Coimbra, Fac Med Coimbra, Ctr Neurosci & Cell Biol, P-3004504 Coimbra, Portugal
[2] Univ Coimbra, Fac Med Coimbra, Inst Biochem, P-3004504 Coimbra, Portugal
来源：
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS | 2005年 / 4卷 / 04期
关键词：
alpha-synuclein; neuronal circuits; oxidative stress; mitochondria; proteasome; neuroinflammation; cell death; therapeutics;
D O I：
10.2174/1568007054546072
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Parkinson's disease (PD), considered one of the major neurological disorders, is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by the presence of intraneuronal cytoplasmic inclusions called Lewy bodies. The causes for degeneration of PD neurons remain unclear, however, recent findings contributed to clarify this issue. This review will discuss the current understanding of the mechanisms underlying Parkinson's disease pathogenesis, focusing on the current and potential therapeutic strategies for human treatment.
引用
收藏
页码：405 / 419
页数：15
相关论文
共 239 条
[1]   Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system [J].
Abeliovich, A ;
Schmitz, Y ;
Fariñas, I ;
Choi-Lundberg, D ;
Ho, WH ;
Castillo, PE ;
Shinsky, N ;
Verdugo, JMG ;
Armanini, M ;
Ryan, A ;
Hynes, M ;
Phillips, H ;
Sulzer, D ;
Rosenthal, A .
NEURON, 2000, 25 (01) :239-252
[2]   Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra [J].
Alam, ZI ;
Jenner, A ;
Daniel, SE ;
Lees, AJ ;
Cairns, N ;
Marsden, CD ;
Jenner, P ;
Halliwell, B .
JOURNAL OF NEUROCHEMISTRY, 1997, 69 (03) :1196-1203
[3]   Behavioral changes associated with deep brain stimulation surgery for Parkinson’s disease [J].
Karen E. Anderson ;
Jake Mullins .
Current Neurology and Neuroscience Reports, 2003, 3 (4) :306-313
[4]  
Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25
[5]  
ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445
[6]   Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice [J].
Aubin, N ;
Curet, O ;
Deffois, A ;
Carter, C .
JOURNAL OF NEUROCHEMISTRY, 1998, 71 (04) :1635-1642
[7]   Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease [J].
Auluck, PK ;
Chan, HYE ;
Trojanowski, JQ ;
Lee, VMY ;
Bonini, NM .
SCIENCE, 2002, 295 (5556) :865-868
[8]   Parkin and α-synuclein:: Opponent actions in the pathogenesis of Parkinson's disease [J].
Baptista, MJ ;
Cookson, MR ;
Miller, DW .
NEUROSCIENTIST, 2004, 10 (01) :63-72
[9]   Adenosine A2A receptor antagonist treatment of Parkinson's disease [J].
Bara-Jimenez, W ;
Sherzai, A ;
Dimitrova, T ;
Favit, A ;
Bibbiani, F ;
Gillespie, M ;
Morris, MJ ;
Mouradian, MM ;
Chase, TN .
NEUROLOGY, 2003, 61 (03) :293-296
[10]   PARTIAL DOPAMINE AGONIST THERAPY OF LEVODOPA-INDUCED DYSKINESIAS [J].
BARONTI, F ;
MOURADIAN, MM ;
CONANT, KE ;
GIUFFRA, M ;
BRUGHITTA, G ;
CHASE, TN .
NEUROLOGY, 1992, 42 (06) :1241-1243
12345678910